Exploitation timeline
Threadlinqs has recorded 7 Telit Cinterion CVEs published between and . The busiest month was 2023-11 (7 new CVEs). None of them is listed in CISA KEV yet.
Most exploited vulnerabilities
Ranked with CISA KEV listings first, then EPSS exploit probability, then CVSS score. Showing 7 of 7 tracked Telit Cinterion CVEs.
- CVE-2023-47610high 8.1EPSS 1.7%
- CVE-2023-47612medium 6.8EPSS 0.3%
- CVE-2023-47616low 2.4EPSS 0.3%
- CVE-2023-47613medium 4.4EPSS 0.2%
- CVE-2023-47614low 3.3EPSS 0.2%
- CVE-2023-47611high 7.8EPSS 0.2%
- CVE-2023-47615low 3.3EPSS 0.2%
Products affected
Threadlinqs normalises CPE and CNA product records across all 7 CVEs; 19 distinct Telit Cinterion products are affected. The most frequently affected:
- EHS6 7 CVEs
- EHS8 7 CVEs
- BGS5 6 CVEs
- EHS5 5 CVEs
- ELS61 4 CVEs
- ELS81 4 CVEs
- PDS5 4 CVEs
- PDS6 4 CVEs
- PDS8 4 CVEs
- PLS62 4 CVEs
- EHS5-E 2 CVEs
- EHS5-US 2 CVEs
- EHS5-US Rel.4 2 CVEs
- EHS6 Rel.2 2 CVEs
- EHS6 Rel.3 2 CVEs
- EHS6 Rel.4 2 CVEs
- EHS6-A Rel.4 2 CVEs
- EHS8 Rel.4 2 CVEs
- ELS61-AUS 2 CVEs
Threat activity
1 tracked threat campaign reference Telit Cinterion products or exploit Telit Cinterion CVEs:
How to prioritise Telit Cinterion patching
This order follows the data Threadlinqs holds for Telit Cinterion, not a generic severity checklist:
- No Telit Cinterion CVE is in CISA KEV yet, so rank by exploit probability instead.
- Outside KEV, the highest EPSS scores are CVE-2023-47610 (1.7%), CVE-2023-47612 (0.3%), CVE-2023-47616 (0.3%).
- 0 CVEs score Critical and 2 High on CVSS v3 (maximum 8.1, average 5.2); sequence these after KEV and high-EPSS items.
- 1 CVE has a public exploit or proof of concept recorded, which shortens the time from disclosure to attack.
About this data
Vendor attribution comes from the CNA and CPE product records of each CVE, folded to one vendor name; CVSS, EPSS and KEV status are read from the Threadlinqs CVE catalog; campaign and actor links come from tracked threat records. Counts reflect the data as of 2026-11-19 and refresh daily.